Scientific Reports (Oct 2021)

Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19

  • Kimon Stamatelopoulos,
  • Georgios Georgiopoulos,
  • Kenneth F. Baker,
  • Giusy Tiseo,
  • Dimitrios Delialis,
  • Charalampos Lazaridis,
  • Greta Barbieri,
  • Stefano Masi,
  • Nikolaos I. Vlachogiannis,
  • Kateryna Sopova,
  • Alessandro Mengozzi,
  • Lorenzo Ghiadoni,
  • Ina Schim van der Loeff,
  • Aidan T. Hanrath,
  • Bajram Ajdini,
  • Charalambos Vlachopoulos,
  • Meletios A. Dimopoulos,
  • Christopher J. A. Duncan,
  • Marco Falcone,
  • Konstantinos Stellos,
  • the Pisa COVID-19 Research Group,
  • Newcastle COVID-19 Research Group

DOI
https://doi.org/10.1038/s41598-021-99050-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Accurate risk stratification in COVID-19 patients consists a major clinical need to guide therapeutic strategies. We sought to evaluate the prognostic role of estimated pulse wave velocity (ePWV), a marker of arterial stiffness which reflects overall arterial integrity and aging, in risk stratification of hospitalized patients with COVID-19. This retrospective, longitudinal cohort study, analyzed a total population of 1671 subjects consisting of 737 hospitalized COVID-19 patients consecutively recruited from two tertiary centers (Newcastle cohort: n = 471 and Pisa cohort: n = 266) and a non-COVID control cohort (n = 934). Arterial stiffness was calculated using validated formulae for ePWV. ePWV progressively increased across the control group, COVID-19 survivors and deceased patients (adjusted mean increase per group 1.89 m/s, P < 0.001). Using a machine learning approach, ePWV provided incremental prognostic value and improved reclassification for mortality over the core model including age, sex and comorbidities [AUC (core model + ePWV vs. core model) = 0.864 vs. 0.755]. ePWV provided similar prognostic value when pulse pressure or hs-Troponin were added to the core model or over its components including age and mean blood pressure (p < 0.05 for all). The optimal prognostic ePWV value was 13.0 m/s. ePWV conferred additive discrimination (AUC: 0.817 versus 0.779, P < 0.001) and reclassification value (NRI = 0.381, P < 0.001) over the 4C Mortality score, a validated score for predicting mortality in COVID-19 and the Charlson comorbidity index. We suggest that calculation of ePWV, a readily applicable estimation of arterial stiffness, may serve as an additional clinical tool to refine risk stratification of hospitalized patients with COVID-19 beyond established risk factors and scores.